FBXW7 and diffuse large B-cell lymphoma: Importantly, new variants emerged in different patients such as those of PIM1, BIRC3, and FBXW7. This observation suggests that mutations responsible for relapse or refractory disease in individual DLBCL patients can potentially be determined noninvasively using a blood-based test.